Gemifloxacin (GEM) is a potent fluoroquinolone with excellent activity against respiratory tract infection (RTI) pathogens, including S. pneumoniae (SP). Pooled data from 17 phase III clinical trials for GEM with community-acquired pneumonia, acute bacterial sinusitis & acute exacerbation of chronic bronchitis patients (pts.
530 Pts where SP was the sole pathogen & SP susceptibility known, were evaluated.Clinical success at end of therapy (EOT) & at follow-up (FU, approx. 1-3 weeks after treatment) was studied. Main comparators (CMP) were cefuroxime (61 pts), amoxicillin-clavulanate (37 pts), trovafloxacin (34 pts), cefuroxime & clarithromycin (28 pts), levofloxacin or clarithromycin (11 pts). Percentage success based on susceptibility to penicillin G (Pen) and/or macrolides (Mac) is shown (Table, S = susceptible, NS = non-susceptible, R = resistant, N = pts/group).
GEM showed good clinical success against all resistance phenotypes. These data support the use of GEM in the treatment of RTI, especially where MacR SP prevails.
The emergence of antibacterial resistance may effect empirical therapy, gemifloxacin has been shown to be effective against resistant phenotypes of th emost common bacterial respiratory pathogen.
PhenotypeTreatment% Success (N)EOTFUAll SPGEM92.5% (321)88.8% (321)CMP90.4% (209)86.0% (207)PenSGEM93.3% (252)88.9% (252)CMP91.0% (166)86.0% (164)PenNSGEM89.7% (68)88.2% (68)CMP88.4% (43)86.0% (43)MacSGEM93.0% (256)88.3% (256)CMP92.0% (175)86.2% (174)MacRGEM90.3% (62)90.3% (62)CMP81.3% (32)83.9% (31)PenR & MacRGEM85.7% (28)85.7% (28)CMP82.4% (17)82.4% (17)
Thomas File, Consultant fee, speaker bureau, advisory committee, etc. TF & LM are consultants to Oscient.